Rybrevant Plus Lazertinib—A New Era In Targeted Lung Cancer Treatment
The treatment landscape for non-small cell lung cancer (NSCLC) continues to evolve, and the latest data from Johnson & Johnson’s Janssen Pharmaceuticals
Hassan graduated with a Master’s degree in Chemical Engineering from the University of Chester (UK). He currently works as a design engineering consultant for one of the largest engineering firms in the world along with being an associate member of the Institute of Chemical Engineers (IChemE).